-
1
-
-
84911499584
-
Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up clinical practice guidelines
-
Escudier B, Kataja V: Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up clinical practice guidelines. Ann Oncol 2014;25(suppl 3):49-56.
-
(2014)
Ann Oncol
, vol.25
, pp. 49-56
-
-
Escudier, B.1
Kataja, V.2
-
2
-
-
20144388609
-
Adjuvant treatment with interleukin-2-and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
-
Atzpodien J, Schmitt E, Gertenbach U, Fornara P, Heynemann H, Maskow A, et al. Adjuvant treatment with interleukin-2-and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 2005;92:843-846.
-
(2005)
Br J Cancer
, vol.92
, pp. 843-846
-
-
Atzpodien, J.1
Schmitt, E.2
Gertenbach, U.3
Fornara, P.4
Heynemann, H.5
Maskow, A.6
-
3
-
-
0025247712
-
Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma: A randomized trial
-
Steineck G, Strander H, Carbin BE, Borgström E, Wallin L, Achtnich U, et al. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma: a randomized trial. Acta Oncol 1990;29:155-162.
-
(1990)
Acta Oncol
, vol.29
, pp. 155-162
-
-
Steineck, G.1
Strander, H.2
Carbin, B.E.3
Borgström, E.4
Wallin, L.5
Achtnich, U.6
-
4
-
-
2442737061
-
Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer
-
Pyrhönen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17:2859-2867.
-
(1999)
J Clin Oncol
, vol.17
, pp. 2859-2867
-
-
Pyrhönen, S.1
Salminen, E.2
Ruutu, M.3
Lehtonen, T.4
Nurmi, M.5
Tammela, T.6
-
5
-
-
84965188394
-
Immunotherapy for advanced renal cell cancer
-
Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T: Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005:CD001425.
-
(2005)
Cochrane Database Syst Rev
, pp. CD001425
-
-
Coppin, C.1
Porzsolt, F.2
Awa, A.3
Kumpf, J.4
Coldman, A.5
Wilt, T.6
-
6
-
-
0042914703
-
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer
-
Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127-3132.
-
(2003)
J Clin Oncol
, vol.21
, pp. 3127-3132
-
-
Yang, J.C.1
Sherry, R.M.2
Steinberg, S.M.3
Topalian, S.L.4
Schwartzentruber, D.J.5
Hwu, P.6
-
7
-
-
16644401873
-
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
-
McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-141.
-
(2005)
J Clin Oncol
, vol.23
, pp. 133-141
-
-
McDermott, D.F.1
Regan, M.M.2
Clark, J.I.3
Flaherty, L.E.4
Weiss, G.R.5
Logan, T.F.6
-
8
-
-
0028929682
-
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy
-
Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-696.
-
(1995)
J Clin Oncol
, vol.13
, pp. 688-696
-
-
Fyfe, G.1
Fisher, R.I.2
Rosenberg, S.A.3
Sznol, M.4
Parkinson, D.R.5
Louie, A.C.6
-
9
-
-
0033847587
-
Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma
-
Fisher RI, Rosenberg SA, Fyfe G: Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000;6(suppl 1):55-57.
-
(2000)
Cancer J Sci Am
, vol.6
, pp. 55-57
-
-
Fisher, R.I.1
Rosenberg, S.A.2
Fyfe, G.3
-
10
-
-
76749116183
-
Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): An open-label randomised trial
-
Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, Aitchison M, et al. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 2010;375:641-648.
-
(2010)
Lancet
, vol.375
, pp. 641-648
-
-
Gore, M.E.1
Griffin, C.L.2
Hancock, B.3
Patel, P.M.4
Pyle, L.5
Aitchison, M.6
-
11
-
-
37349080670
-
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial
-
Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-2111.
-
(2007)
Lancet
, vol.370
, pp. 2103-2111
-
-
Escudier, B.1
Pluzanska, A.2
Koralewski, P.3
Ravaud, A.4
Bracarda, S.5
Szczylik, C.6
-
12
-
-
56749161699
-
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
-
Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422-5428.
-
(2008)
J Clin Oncol
, vol.26
, pp. 5422-5428
-
-
Rini, B.I.1
Halabi, S.2
Rosenberg, J.E.3
Stadler, W.M.4
Vaena, D.A.5
Ou, S.S.6
-
13
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.
-
(2010)
N Engl J Med
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
Weber, R.W.4
Sosman, J.A.5
Haanen, J.B.6
-
14
-
-
84908354848
-
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial
-
Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109-1117.
-
(2014)
Lancet
, vol.384
, pp. 1109-1117
-
-
Robert, C.1
Ribas, A.2
Wolchok, J.D.3
Hodi, F.S.4
Hamid, O.5
Kefford, R.6
-
15
-
-
79959772576
-
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
-
Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-2526.
-
(2011)
N Engl J Med
, vol.364
, pp. 2517-2526
-
-
Robert, C.1
Thomas, L.2
Bondarenko, I.3
O'Day, S.4
Weber, J.5
Garbe, C.6
-
16
-
-
84925222119
-
Nivolumab in previously untreated melanoma without BRAF mutation
-
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-330.
-
(2015)
N Engl J Med
, vol.372
, pp. 320-330
-
-
Robert, C.1
Long, G.V.2
Brady, B.3
Dutriaux, C.4
Maio, M.5
Mortier, L.6
-
17
-
-
84925221855
-
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
-
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372:311-319.
-
(2015)
N Engl J Med
, vol.372
, pp. 311-319
-
-
Ansell, S.M.1
Lesokhin, A.M.2
Borrello, I.3
Halwani, A.4
Scott, E.C.5
Gutierrez, M.6
-
19
-
-
37349072460
-
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
-
Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007;30:825-830.
-
(2007)
J Immunother
, vol.30
, pp. 825-830
-
-
Yang, J.C.1
Hughes, M.2
Kammula, U.3
Royal, R.4
Sherry, R.M.5
Topalian, S.L.6
-
20
-
-
79551717184
-
Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma
-
Rini BI, Stein M, Shannon P, Eddy S, Tyler A, Stephenson JJ, et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 2011;117:758-767.
-
(2011)
Cancer
, vol.117
, pp. 758-767
-
-
Rini, B.I.1
Stein, M.2
Shannon, P.3
Eddy, S.4
Tyler, A.5
Stephenson, J.J.6
-
21
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454.
-
(2012)
N Engl J Med
, vol.366
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
Gettinger, S.N.4
Smith, D.C.5
McDermott, D.F.6
-
22
-
-
84880706331
-
Survival, safety, and response duration results of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in a phase i trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up (abstract)
-
Drake CG, McDermott DF, Sznol M, Choueiri TK, Kluger HM, Powderly JD, et al. Survival, safety, and response duration results of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): long-term patient follow-up (abstract). J Clin Oncol 2013;31(suppl):4514.
-
(2013)
J Clin Oncol
, vol.31
, pp. 4514
-
-
Drake, C.G.1
McDermott, D.F.2
Sznol, M.3
Choueiri, T.K.4
Kluger, H.M.5
Powderly, J.D.6
-
23
-
-
84921386441
-
Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial (abstract)
-
Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel T, Harrison MR, et al. Nivolumab for metastatic renal cell carcinoma (mRCC): results of a randomized, dose-ranging phase II trial (abstract). J Clin Oncol 2014;32(suppl 15):5009.
-
(2014)
J Clin Oncol
, vol.32
, pp. 5009
-
-
Motzer, R.J.1
Rini, B.I.2
McDermott, D.F.3
Redman, B.G.4
Kuzel, T.5
Harrison, M.R.6
-
24
-
-
84880264878
-
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC) [abstract]
-
Cho DC, Sosman JA, Sznol M, Gordon MS, Hollbecque A, Hamid O, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 2013;31(suppl):4505.
-
(2013)
J Clin Oncol
, vol.31
, pp. 4505
-
-
Cho, D.C.1
Sosman, J.A.2
Sznol, M.3
Gordon, M.S.4
Hollbecque, A.5
Hamid, O.6
-
25
-
-
84938313517
-
Safety and efficacy, of MPDL3280A (anti-PDL1) in combination with bevacizumab (BEV) and/or chemotherapy (CHEMO) in patients (PTS) with locally advanced or metastastic solid tumours
-
Lieu C, Bendell J, Powderly JD, Pishvaian MJ, Hochster H, Eckhardt SG, et al. Safety and efficacy, of MPDL3280A (anti-PDL1) in combination with bevacizumab (BEV) and/or chemotherapy (CHEMO) in patients (PTS) with locally advanced or metastastic solid tumours. Ann Onc 2014;25:iv361-iv372.
-
(2014)
Ann Onc
, vol.25
, pp. iv361-iv372
-
-
Lieu, C.1
Bendell, J.2
Powderly, J.D.3
Pishvaian, M.J.4
Hochster, H.5
Eckhardt, S.G.6
-
26
-
-
84862903106
-
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
-
Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-2465.
-
(2012)
N Engl J Med
, vol.366
, pp. 2455-2465
-
-
Brahmer, J.R.1
Tykodi, S.S.2
Chow, L.Q.M.3
Hwu, W.-J.4
Topalian, S.L.5
Hwu, P.6
-
27
-
-
33645736792
-
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up
-
Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006;66:3381-3385.
-
(2006)
Cancer Res
, vol.66
, pp. 3381-3385
-
-
Thompson, R.H.1
Kuntz, S.M.2
Leibovich, B.C.3
Dong, H.4
Lohse, C.M.5
Webster, W.S.6
-
28
-
-
84925969185
-
Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: Results from COMPARZ, a randomized controlled trial
-
Choueiri TK, Figueroa DJ, Fay AP, Signoretti S, Liu Y, Gagnon R, et al. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clin Cancer Res 2015;21:1071-1077.
-
(2015)
Clin Cancer Res
, vol.21
, pp. 1071-1077
-
-
Choueiri, T.K.1
Figueroa, D.J.2
Fay, A.P.3
Signoretti, S.4
Liu, Y.5
Gagnon, R.6
-
29
-
-
84984919880
-
PD-L1 expression in nonclear-cell renal cell carcinoma
-
Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, Albiges L, et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol 2014;25:2178-2184.
-
(2014)
Ann Oncol
, vol.25
, pp. 2178-2184
-
-
Choueiri, T.K.1
Fay, A.P.2
Gray, K.P.3
Callea, M.4
Ho, T.H.5
Albiges, L.6
-
30
-
-
84914148032
-
Phase 1 study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (MRCC)
-
Hammers H, Plimack ER, Infante JR, Ernstoff B, Rini BI, McDermott DF, et al. Phase 1 study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (MRCC). ASCO Meeting Abstracts. Ann Oncol 2014;25(suppl 4):4504.
-
(2014)
ASCO Meeting Abstracts. Ann Oncol
, vol.25
, pp. 4504
-
-
Hammers, H.1
Plimack, E.R.2
Infante, J.R.3
Ernstoff, B.4
Rini, B.I.5
McDermott, D.F.6
-
31
-
-
84914176528
-
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC) [abstract]
-
Amin A, Plimack ER, Infante JR, Ernstoff MS, Rini BI, McDermott DF, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 2014;32(suppl):1-15.
-
(2014)
J Clin Oncol
, vol.32
, pp. 1-15
-
-
Amin, A.1
Plimack, E.R.2
Infante, J.R.3
Ernstoff, M.S.4
Rini, B.I.5
McDermott, D.F.6
-
32
-
-
79151471986
-
A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: Clinical and immunological findings
-
Oudard S, Rixe O, Beuselinck B, Linassier C, Banu E, Machiels J-P, et al. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother 2011;60:261-271.
-
(2011)
Cancer Immunol Immunother
, vol.60
, pp. 261-271
-
-
Oudard, S.1
Rixe, O.2
Beuselinck, B.3
Linassier, C.4
Banu, E.5
Machiels, J.-P.6
-
33
-
-
78349284842
-
Vaccination of metastatic renal cancer patients with MVA-5T4: A randomized, double-blind, placebo-controlled phase III study
-
Amato RJ, Hawkins RE, Kaufman HL, Thompson JA, Tomczak P, Szczylik C, et al. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res 2010;16:5539-5547.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 5539-5547
-
-
Amato, R.J.1
Hawkins, R.E.2
Kaufman, H.L.3
Thompson, J.A.4
Tomczak, P.5
Szczylik, C.6
-
34
-
-
0023633145
-
Active specific immunotherapy of renal cell carcinoma patients: A prospective randomized study of hormono-immuno-versus hormonotherapy: Preliminary report of immunological and clinical aspects
-
Adler A, Gillon G, Lurie H, Shaham J, Loven D, Shachter Y, et al. Active specific immunotherapy of renal cell carcinoma patients: a prospective randomized study of hormono-immuno-versus hormonotherapy: preliminary report of immunological and clinical aspects. J Biol Response Mod 1987;6:610-624.
-
(1987)
J Biol Response Mod
, vol.6
, pp. 610-624
-
-
Adler, A.1
Gillon, G.2
Lurie, H.3
Shaham, J.4
Loven, D.5
Shachter, Y.6
-
35
-
-
0030006748
-
Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and Bacillus Calmette-Guerin: Five-year results of a prospective randomized study
-
Galligioni E, Quaia M, Merlo A, Carbone A, Spada A, Favaro D, et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and Bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer 1996;77:2560-2566.
-
(1996)
Cancer
, vol.77
, pp. 2560-2566
-
-
Galligioni, E.1
Quaia, M.2
Merlo, A.3
Carbone, A.4
Spada, A.5
Favaro, D.6
-
36
-
-
10744230275
-
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial
-
Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363:594-599.
-
(2004)
Lancet
, vol.363
, pp. 594-599
-
-
Jocham, D.1
Richter, A.2
Hoffmann, L.3
Iwig, K.4
Fahlenkamp, D.5
Zakrzewski, G.6
-
37
-
-
46749085802
-
An adjuvant autologous therapeutic vaccine (HSPPC-96; Vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: A multicentre, open-label, randomised phase III trial
-
Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008;372:145-154.
-
(2008)
Lancet
, vol.372
, pp. 145-154
-
-
Wood, C.1
Srivastava, P.2
Bukowski, R.3
Lacombe, L.4
Gorelov, A.I.5
Gorelov, S.6
-
38
-
-
0035863285
-
Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: A multicentric randomized study
-
Pizzocaro G, Piva L, Colavita M, Ferri S, Artusi R, Boracchi P, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001;19:425-431.
-
(2001)
J Clin Oncol
, vol.19
, pp. 425-431
-
-
Pizzocaro, G.1
Piva, L.2
Colavita, M.3
Ferri, S.4
Artusi, R.5
Boracchi, P.6
-
39
-
-
0038514165
-
Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: An Eastern Cooperative Oncology Group/Intergroup Trial
-
Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup Trial. J Clin Oncol 2003;21:1214-1222.
-
(2003)
J Clin Oncol
, vol.21
, pp. 1214-1222
-
-
Messing, E.M.1
Manola, J.2
Wilding, G.3
Propert, K.4
Fleischmann, J.5
Crawford, E.D.6
-
40
-
-
0041411517
-
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomized trial
-
Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003;21:3133-3140.
-
(2003)
J Clin Oncol
, vol.21
, pp. 3133-3140
-
-
Clark, J.I.1
Atkins, M.B.2
Urba, W.J.3
Creech, S.4
Figlin, R.A.5
Dutcher, J.P.6
-
41
-
-
84916641707
-
Adjuvant low-dose interleukin-2 (IL-2) plus interferon-alpha (IFN-α) in operable renal cell cancer (RCC): A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC)
-
Passalacqua R, Buzio C, Buti S, Labianca R, Porta C, Boni C, et al. Adjuvant low-dose interleukin-2 (IL-2) plus interferon-alpha (IFN-α) in operable renal cell cancer (RCC): a phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC). J Immunother 2014;37:440-447.
-
(2014)
J Immunother
, vol.37
, pp. 440-447
-
-
Passalacqua, R.1
Buzio, C.2
Buti, S.3
Labianca, R.4
Porta, C.5
Boni, C.6
-
42
-
-
84891629295
-
Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: Results of a phase III randomised European Organisation for Research and Treatment of Cancer
-
Aitchison M, Bray CA, van Poppel H, Sylvester R, Graham J, Innes C, et al. Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer. Eur J Cancer 2014;50:70-77.
-
(2014)
Eur J Cancer
, vol.50
, pp. 70-77
-
-
Aitchison, M.1
Bray, C.A.2
Van Poppel, H.3
Sylvester, R.4
Graham, J.5
Innes, C.6
|